Busulfan, fludarabine and atg (DrugBank: Busulfan, Fludarabine)
18 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
19 | Lysosomal storage disease | 0 |
28 | Systemic amyloidosis | 0 |
36 | Epidermolysis bullosa | 0 |
46 | Malignant rheumatoid arthritis | 0 |
49 | Systemic lupus erythematosus | 0 |
51 | Scleroderma | 0 |
60 | Aplastic anemia | 0 |
61 | Autoimmune hemolytic anemia | 0 |
62 | Paroxysmal nocturnal hemoglobinuria | 0 |
65 | Primary immunodeficiency | 1 |
85 | Idiopathic interstitial pneumonia | 0 |
96 | Crohn disease | 0 |
164 | Oculocutaneous albinism | 0 |
283 | Acquired pure red cell aplasia | 0 |
284 | Diamond-Blackfan anemia | 0 |
285 | Fanconi anemia | 0 |
326 | Osteopetrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00228852 (ClinicalTrials.gov) | April 2004 | 27/9/2005 | IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency | Phase I/II Trial of De-Escalation of Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency | T-Cell Immune Deficiency Diseases;Severe Combined Immunodeficiency | Drug: Busulfan, Fludarabine and ATG | Emory University | NULL | Completed | N/A | N/A | Both | Phase 1;Phase 2 | United States |